A Prescription for Successful Collaborations in Pharma

In this blog I want to highlight what I consider to be 7 Key Points for Successful Collaborations in Pharmaceuticals (although they can equally apply elsewhere).  I have also taken the opportunity to list some actions that leaders could take for each of the 7 points.

1. The Power of Purpose

In the dynamic landscape of the pharmaceutical industry, where innovation is paramount and patient outcomes are central, collaborations play a pivotal role in driving progress – whether these are within your business or with external organisations. However, the success of these collaborations hinges not just on technical expertise, the latest technology or financial investment, but on a deeper foundation: starting with WHY.

At the core of any effective collaboration lies a clear sense of purpose—a compelling reason why stakeholders come together to pursue shared goals. This sense of purpose is especially crucial in the pharmaceutical industry, where the ultimate aim is to improve healthcare outcomes and enhance patient well-being.

One notable example of starting with why can be seen in initiatives like the Myelin Repair Foundation’s Accelerated Research Collaboration. By aligning stakeholders around a common purpose—to address systemic problems in medical research and commercial drug development—the collaboration has been able to drive meaningful change and innovation in the field.

So, why is starting with why so important in collaborations within the pharmaceutical industry?

Firstly, it provides a unifying vision that inspires and motivates all stakeholders involved. When teams understand the purpose behind their work, they are more engaged, committed, and driven to achieve collective success.

Secondly, starting with why helps prioritise patient-centricity—a cornerstone of pharmaceutical collaborations. By anchoring collaborative efforts around improving patient outcomes, stakeholders ensure that their work remains focused on addressing real-world healthcare needs.

Lastly, starting with why fosters alignment and cohesion among diverse stakeholders. In an industry where collaborations often involve multiple organisations with different priorities and objectives, a shared sense of purpose serves as a guiding light, enabling teams to work together seamlessly towards a common goal.

To effect meaningful change, here’s three actions leaders could take:

• Co-create a compelling vision that emphasises patient-centricity and inspires stakeholders to rally around shared goals.
• Communicate the why behind collaborative efforts regularly, consistently and transparently, ensuring that all team members understand and internalise the overarching purpose.
• Foster a culture of purpose-driven collaboration by adapting the operating model, while incentivising behaviours and actions that align with the shared vision, values and goals of the initiative.

2. Navigating your Frontiers: Courage and Presence in Collaborations

In the realm of pharmaceutical collaborations, leadership isn’t just about making decisions – it’s about understanding the complex interplay between courage, authenticity, and self-perception. My good friend Steve Hearsum referenced the appeal of “mini selves” in a recent LinkedIn post, to help shed light on how our interactions shape not only our perceptions of others but also our own identities.

Leaders in the pharmaceutical industry must recognise the power of self-perception and presence in shaping their leadership approach. By understanding that our beliefs about ourselves and others are fluid and shaped by both our history and interactions, leaders can cultivate a deeper sense of authenticity and empathy in their collaborations.

To effect meaningful change, here’s three actions leaders could take:

• Be Courageous to Embrace Vulnerability: Leaders should be willing to acknowledge their own insecurities and limitations, fostering an environment of psychological safety where team members feel comfortable expressing themselves without fear of judgment.
• Foster Diversity and Inclusion: Recognising the multiplicity of selves within their teams, leaders should actively seek out diverse perspectives and experiences, creating opportunities for collaboration and innovation that transcend traditional boundaries.
• Lead with Empathy: By understanding the impact of their actions and beliefs on others, leaders can cultivate empathy and compassion in their interactions, building trust and fostering authentic connections within their teams and across collaborations.

3. Pushing Boundaries: How Learning at the Edge Fuels Learning and Innovation

Innovation often lies at the intersection of different disciplines and perspectives. Encouraging learning at the edge—where comfort zones are challenged and unconventional ideas are explored—is crucial for fostering successful collaborations and breakthroughs.

Pharmaceutical collaborations thrive on the synergy of diverse expertise and innovative thinking. Bernard Munos highlights how Eli Lilly’s success with insulin in the 1920s was a result of venturing beyond their core competencies, harnessing external knowledge to solve unprecedented challenges. This kind of boundary-crossing thinking is essential for tackling today’s complex biomedical problems.

Examples like the contests held by Innocentive demonstrate that diverse solver populations, often from outside the core field, are more likely to provide innovative solutions. These contests prove that breakthroughs frequently come from those willing to operate on the edge, embracing risk and unconventional thinking.

To effect meaningful change, here’s three actions leaders could take:

• Cultivate a culture of experimentation by creating an environment where experimentation is encouraged, and failures are seen as learning opportunities rather than setbacks. This involves providing resources and support for innovative projects, even those that fall outside traditional areas of expertise.
• Facilitate cross-disciplinary collaborations by actively promoting partnerships between different disciplines and institutions. Initiatives like Biogen’s Innovation Insourcing Initiative exemplify the value of integrating academic researchers with corporate resources to advance late-stage biology ideas. Such collaborations can spark innovative solutions that might not emerge within a single domain.
• Encourage risk-taking and diverse thinking, by encouraging team members to step out of their comfort zones and explore new ideas. As seen in the MATLAB Programming Contest, the most significant improvements come when participants build on each other’s ideas. Creating opportunities for knowledge sharing and collaboration can lead to transformative insights and advancements.

4. Blueprint for Innovation: How Operating Models enable Successful Collaborations

In the pharmaceutical industry, the design of an organisation’s operating model is critical to fostering effective collaborations and driving innovation. The Galbraith Star Model provides a robust framework to reflect on, it highlights five key elements leaders need to pay attention to, to create successful collaborations: Strategy, Structure, Processes, Rewards, and People. By aligning these elements, pharmaceutical leaders can create an environment conducive to collaboration and breakthrough innovations.

An optimal operating model ensures that all aspects of the organisation work cohesively towards common goals. In pharmaceutical collaborations, this is vital because the complexity and risk involved require seamless integration of diverse expertise and resources.

Strategy is the starting point. It defines the direction and scope of the collaboration. For instance, the successful partnership between Merck and AstraZeneca on a combination therapy for cancer was driven by a clear strategic vision to leverage complementary strengths for a competitive advantage.

Structure follows strategy, determining the arrangement of roles and responsibilities. The Cancer Genome Atlas (TCGA) project exemplifies a well-structured collaboration involving government, academia, and industry to sequence tumour genomes. Such a collaborative structure enables sharing of vast datasets and expertise, enhancing research outcomes.

Processes are essential for ensuring smooth operation and communication within the collaboration. The I-SPY 2 TRIAL, a public-private collaboration, redefined traditional clinical trial processes to reduce time, cost, and volunteer requirements significantly, demonstrating how innovative processes can accelerate drug development.

Rewards align incentives with collaborative goals. Prizes for solving scientific problems, as seen in the Innocentive contests, encourage diverse problem-solving approaches and draw expertise from outside the traditional pharma domain, increasing the likelihood of breakthroughs.

People are at the heart of the operating model. Ensuring the right talent is in place and fostering a culture of collaboration and innovation is crucial. Biogen’s Innovation Insourcing Initiative, which brings academic researchers into the company, highlights the importance of integrating external talent and ideas.

To effect meaningful change, here’s three actions leaders could take:

• Clearly define the strategic objectives of collaborations and ensure they align with the overall vision of the organisation / partners. This alignment provides a roadmap for all partners, fostering a shared sense of purpose and direction.
• Create structures that promote cross-functional teams and fluid communication channels. For example, establishing joint task forces or innovation hubs can facilitate the integration of diverse expertise and accelerate problem-solving.
• Develop processes that encourage open communication, knowledge sharing, and joint decision-making. Additionally, implement reward systems that recognise collaborative achievements and contributions, motivating participants to engage fully and innovate.

5. One Source to Rule Them All:  A Single Source of Truth

The ability to harness vast and often conflicting datasets is crucial for driving innovation and making informed decisions. Establishing a single source of truth is essential to ensure consistency, validity, reliability, regulatory confidence, and efficiency will drive more cost-effective and innovative outcomes.

A single source of truth ensures that all stakeholders in a collaboration access and work from the same data, minimising discrepancies and enhancing trust. In an industry where data integrity can significantly impact patient outcomes, having a unified data source is not just beneficial—it’s vital.

For example, The Cancer Genome Atlas (TCGA), a collaborative effort among government, academia, and industry, successfully sequenced various tumour genomes by maintaining a high level of data integrity. The unified dataset allowed researchers to draw more accurate conclusions and develop effective cancer treatments.

Similarly, the collaboration between Merck and AstraZeneca on a combination therapy for cancer underscores the importance of consistent data. By maintaining a single source of truth, both companies were able to streamline their research processes, reduce redundancy, and enhance the accuracy of their findings.

To effect meaningful change, here’s three actions leaders could take:

• Encourage open communication and regular data reviews among all stakeholders. This helps to quickly identify and resolve any data discrepancies, ensuring that everyone remains aligned and informed. Regular updates and transparent reporting mechanisms are key to maintaining a single source of truth.
• Invest in advanced data management technologies that ensure data is collected, stored, and processed consistently across all platforms. This includes utilising cloud-based solutions and where possible blockchain technology to maintain data integrity and accessibility.
• Establish clear data governance policies and protocols that define how data is to be managed, shared, and used. This includes appointing data stewards to oversee data quality and ensuring that all team members are trained in best practices for data handling.

6. Beyond Skills: Why Cooperative Behaviours Matter in Pharma Collaborations

Successful collaboration hinges on the careful selection of team members. The synergy created through effective teamwork often leads to breakthroughs that would be unattainable individually. However, this synergy can be disrupted by the presence of individuals who are more self-oriented than team-oriented. Understanding the impact of these dynamics and strategically forming teams can significantly enhance collaboration outcomes.

A study published in 2006 in Research in Organisational Behaviour revealed the detrimental effects of including self-oriented individuals in teams. These individuals exhibited behaviours such as slacking (social loafing), negativity, and norm violations, which collectively hindered team performance.

Pharmaceutical collaborations require high levels of cooperation and trust due to the complexity and stakes involved. The I-SPY 2 trial, a collaborative effort in breast cancer research, exemplifies the benefits of a well-coordinated team. Such trials rely on seamless cooperation to integrate vast amounts of data and expertise from diverse stakeholders. Introducing self-oriented individuals into these teams can slow progress, diminish morale, and lead to suboptimal results.

A 2022 study by researchers from the University of Groningen underscores the importance of meritocratic matching, which involves selecting team members based on their cooperative behaviours rather than just availability or skill sets. This method ensures that team dynamics remain positive and productive, leading to better outcomes in collaborative research.

To effect meaningful change, here’s three actions leaders could take:

• Evaluate potential team members based on their demonstrated prosocial behaviours rather than relying solely on self-reports or past affiliations. This approach minimises the risk of incorporating disruptive elements into the team.
• Encourage prosocial individuals to seek out and collaborate with like-minded peers. This natural segregation helps to isolate pro-self individuals, maintaining a cohesive and cooperative team environment even when complete information about individual behaviours is lacking.
• Regularly assess team interactions and dynamics to identify any emerging pro-self behaviours. Early detection and intervention can prevent these behaviours from undermining the team’s effectiveness. This may involve providing feedback, additional training, or, if necessary, reassigning team members.

7. Ecosystem Synergy: Revolutionising Collaborations

Adopting an ecosystem approach can create a collaborative environment that is more innovative, efficient, and responsive to the needs of all stakeholders. An ecosystem approach ensures that these collaborations are not only effective but also sustainable and scalable. This approach recognises that successful partnerships extend beyond immediate stakeholders, incorporating a broader network of collaborators, resources, and shared goals.

The success of Waymo, the autonomous vehicle company, highlights the power of an ecosystem approach. By engaging with multiple stakeholders including technology firms, regulatory bodies, and local communities, Waymo was able to navigate complex challenges and accelerate the development of self-driving technology. Similarly, in pharma, pooling resources and expertise can accelerate innovation and improve outcomes.

An ecosystem approach ensures that all parties, including researchers, clinicians, regulators, and patients, are aligned towards a common goal. This alignment fosters a more cohesive and efficient development process, minimising redundancies and leveraging the strengths of each participant. In contrast, siloed efforts can lead to fragmented and inefficient workflows, hindering progress and innovation.

To effect meaningful change, here’s three actions leaders could take:

• Actively seek to build and maintain diverse networks that include not only traditional partners but also non-traditional stakeholders such as patient advocacy groups, technology firms, and policymakers. This diversity enriches the collaborative process, bringing in fresh perspectives and innovative solutions, much like Waymo’s inclusion of varied stakeholders to advance their technology.
• Transparent and frequent communication is crucial in maintaining trust and alignment within the ecosystem. Leaders should establish clear channels for information sharing and ensure that all partners are kept informed and engaged throughout the collaboration process. Waymo’s success in maintaining open lines of communication across different sectors can serve as a model here.
• Align the goals and performance metrics of all partners to ensure that everyone is working towards the same objectives. This alignment helps to streamline efforts and maintain focus on the shared mission, avoiding conflicts and ensuring that all partners benefit from the collaboration. The coordination in Waymo’s ecosystem demonstrates the effectiveness of aligning diverse stakeholders towards a common goal.

Feel free to contact me at nick.richmond@tricordant.com or book a meeting with me here

Download this blog as PDF